TaiLai Biosciences Raised ￥10M in Pre-A Round of Financing

According to 36Kr.com, Chinese biotechnology company Tailai Biosciences has raised tens of millions of yuan (US$1.4 million) in its Pre-A round funding with participation from Panacea Venture, Kindstar Global, and Kengpeng Medical Angel Fund. Hunger Capital is the exclusive financial advisor of this financing.

TaiLai Biosciences is a biotechnology company founded by medical experts and seasoned scientists, providing disruptive biopsy products and services based on proprietary multi-omics technology. The company has been cooperating with world-renowned hospitals and leaders for advanced cancer screening technology with multi-omics and machine learning based on a great number of clinical data. Its products and services make it possible to locate, identify and intervene in the patients' disease early enough, which could significantly increase the recovery rate.

TaiLai Biosciences has developed several techniques to interpret molecular information to make effective diagnosis in a non-invasive way, and it is developing a series of sample biopsy techniques for all kinds and stages of cancer with a non-invasive way as well. Meanwhile, TaiLai Biosciences is also cooperating with many top hospitals and leading immunotherapy enterprises to develop companion diagnostic techniques for immune-guided medication and cancer recurrence monitoring.

Based on a variety of bio-omics technologies, TaiLai Biosciences provides the high throughput pan-tumor screening product, Meta-Pan™ by using the company's proprietary Matrix-Assisted Laser Desorption/Ionization-Time Of Flight (MALDI-TOF) technology, which is one of the metabolomics analysis technologies.

Panacea Venture is a science-focused venture capital firm focusing on investing in and incubating early-stage life science companies with disruptive and breakthrough technologies and discoveries. The company seeks great ideas or invention leading to first-in-class or best-in-class therapeutics, medical devices, and diagnostics.

Panacea Venture manages both a USD fund and an RMB fund and has an operational office in Shanghai, China. 

Kindstar Global is a Chinese high-tech enterprise that provides advanced specialized inspection services for hospitals. The company is focused on the development and improvement of specialized clinical and personalized medicine.